Published on 21/10/2020 12:55:11 PM | Source: Angel Broking Ltd

Quote on Strides Pharma Ltd By Mr. Yash Gupta, Angel Broking Ltd  ​​​​​​​

Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel 

Download Telegram App before Joining the Channel

Below is the Quote on Strides Pharma Ltd By Mr. Yash Gupta- Equity Research Associate, Angel Broking Ltd  

"Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Ethacrynic Acid Tablets USP, 25 mg from the United States Food & Drug Administration (USFDA). The product is a generic version of Edecrin® Tablets, 25 mg, of Bausch Health Americas, Inc. According to IQVIA MAT August 2020 data, the US market for Ethacrynic Acid Tablets USP, 25 mg is approximately US$ 14 Mn. The product will be manufactured at the company’s flagship facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market. This is positive development for the company."


Above views are of the author and not of the website kindly read disclaimer